Skip to main content
Premium Trial:

Request an Annual Quote

DermTech, Dermpath Ink Marketing Partnership

NEW YORK (GenomeWeb) – DermTech, a private developer of gene expression-based tests for skin diseases, announced today that it has formed a sales and marketing collaboration with Dermpath Diagnostics.

Under the terms of the deal, Dermpath — a Quest Diagnostics-owned dermatopathology services provider — will provide specialty dermatology representatives in up to 10 regional territories across the US to help DermTech in marketing its Pigmented Lesion assay (PLA), which analyzes the expression of two oncogenes to differentiate malignant melanoma from benign pigmented skin lesions.

Additional terms of the arrangement were not disclosed.

"This collaboration will significantly expand our ability to offer the PLA to dermatologists in the US," Sarah Dennison, vice president of marketing at DermTech, said in a statement. 

Michael Kramer, vice president of dermatopathology at Dermpath, added, "We are pleased to align with DermTech in offering their innovative PLA and to further our mission to provide comprehensive dermatopathology services to the medical community."

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.